Pierfitte C, Macouillard G, Thicoïpe M, Chaslerie A, Pehourcq F, Aïssou M, Martinez B, Lagnaoui R, Fourrier A, Bégaud B, Dangoumau J, Moore N
Département de Pharmacologie, Unité de Pharmacologie Clinique, Centre Hospitalier Universitaire de Bordeaux, 33076 Bordeaux Cedex, France.
BMJ. 2001 Mar 24;322(7288):704-8. doi: 10.1136/bmj.322.7288.704.
To determine whether benzodiazepines are associated with an increased risk of hip fracture.
Case-control study.
All incident cases of hip fracture not related to traffic accidents or cancer in patients over 65 years of age. 245 cases were matched to 817 controls.
Emergency department of a university hospital.
Exposure to benzodiazepines and other potential risk or protective factors or lifestyle items.
The use of benzodiazepines as determined from questionnaires, medical records, or plasma samples at admission to hospital was not associated with an increased risk of hip fracture (odds ratio 0.9, 95% confidence interval 0.5 to 1.5). Hip fracture was, however, associated with the use of two or more benzodiazepines, as determined from questionnaires or medical records but not from plasma samples. Of the individual drugs, only lorazepam was significantly associated with an increased risk of hip fracture (1.8, 1.1 to 3.1).
Except for lorazepam, the presence of benzodiazepines in plasma was not associated with an increased risk of hip fracture. The method used to ascertain exposure could influence the results of case-control studies.
确定苯二氮䓬类药物是否与髋部骨折风险增加相关。
病例对照研究。
65岁以上患者中所有与交通事故或癌症无关的髋部骨折新发病例。245例病例与817名对照进行匹配。
一所大学医院的急诊科。
入院时接触苯二氮䓬类药物及其他潜在风险或保护因素或生活方式项目的情况。
通过问卷调查、病历或入院时血浆样本确定的苯二氮䓬类药物使用情况与髋部骨折风险增加无关(比值比0.9,95%置信区间0.5至1.5)。然而,根据问卷调查或病历而非血浆样本确定,髋部骨折与使用两种或更多苯二氮䓬类药物有关。在个别药物中,只有劳拉西泮与髋部骨折风险增加显著相关(1.8,1.1至3.1)。
除劳拉西泮外,血浆中苯二氮䓬类药物的存在与髋部骨折风险增加无关。用于确定接触情况的方法可能会影响病例对照研究的结果。